{"symbol": "RLMD", "name": "Relmada Therapeutics", "next_earnings_utc": 1591696800, "next_earnings_period_start_date_utc": 1585612800, "next_earnings_period_end_date_utc": 1593475200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.5625, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "relmada.com", "year_founded": 2004, "street_address": "880 Third Avenue", "city": "New York", "state": "NY", "zipcode": "10022", "country": "United States", "phone_number": "646-876-3459", "short_description": "Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States.", "long_description": "Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 732700834, "total_enterprise": 617783839, "number_of_employees": 6, "outstanding_shares": 15198109, "eps": -1.968529, "diluted_eps": -1.968529, "earnings_from_cont_operations": -24380335, "gross_profit": null, "cash": 114916995, "total_debt": 0, "total_revenue": null, "cash_from_operations": -14240384, "net_income": -24380335, "ebitda": -23811273, "year_low_stock_price": 38.0, "year_high_stock_price": 49.0, "seekingalpha_follower_count": 1210, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/RLMD.png"}